NCT00412425View on ClinicalTrials.gov

Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Melanoma
Interventions
DRUG

Palonosetron

0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.

Trial Locations (1)

77030

U.T. M.D. Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00412425 - Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting | Biotech Hunter | Biotech Hunter